Clincosm LogoSign in Get a demo

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

Sponsor
Suzhou Connect Biopharmaceuticals, Ltd. (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT04700449
Collaborator
(none)
145
Enrollment
65
Locations
2
Arms
46.1
Anticipated Duration (Months)
2.2
Patients Per Site
0
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

This is a multicenter, multicountry, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC). CBP-307 capsules are administered orally. This study includes stage 1 and stage 2. After screening, subjects will enter the randomized, double-blind, placebo-controlled induction therapy for 12 weeks, i.e., the study stage 1. All subjects who complete 12 weeks of induction therapy (with CBP-307 or placebo) in the study stage 1 and complete all examinations (including colonoscopy) at the week 12 visit can choose to enter the study stage 2 of a total of 40 weeks, including 36 weeks of continuous administration and 4 weeks of safety follow-up after the last dose.

Study Design

Study Type:
Interventional
Actual Enrollment :
145 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
Actual Study Start Date :
Feb 27, 2019
Actual Primary Completion Date :
Feb 23, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: CBP-307 capsules

CBP-307 capsules oral administration.

Drug: CBP-307
CBP-307 capsules oral administration
Placebo Comparator: Placebo capsules

Placebo capsules oral administration.

Drug: Placebo
Placebo capsules oral administration

Outcome Measures

Primary Outcome Measures

  1. Adapted Mayo score [at Week 12]

    Change in adapted Mayo score from baseline at week 12 compared between CBP-307 and placebo

Secondary Outcome Measures

  1. Change in complete Mayo score [at Week 12]

    Change in complete Mayo score from baseline at week 12 after treatment

  2. Comparison of clinical response rate by adapted Mayo score [at Week 12]

    Comparison of clinical response rate at week 12 by adapted Mayo score (defined as a decrease of ≥ 2 points and at least 30% from baseline, accompanied with a decrease of ≥ 1 point from baseline in the rectal bleeding subscore or an absolute rectal bleeding subscore of ≤ 1 point).

  3. Comparison of clinical response rate by complete Mayo score [at Week 12]

    Comparison of clinical response rate at week 12 by complete Mayo score (defined as a decrease of ≥ 3 points and at least 30% from baseline, accompanied with a decrease of ≥ 1 point from baseline in the rectal bleeding subscore or an absolute rectal bleeding subscore of ≤ 1 point).

  4. Comparison of clinical remission rate by adapted Mayo score [at Week 12]

    Comparison of clinical remission rate at week 12 by adapted Mayo score (defined as a rectal bleeding subscore = 0 and a stool frequency subscore ≤ 1, with an Endoscopy subscore ≤ 1 [excluding friability]).

  5. Comparison of clinical remission rate by complete Mayo score [at Week 12]

    Comparison of clinical remission rate at week 12 by complete Mayo score (defined as a total Mayo score of ≤ 2 points with no individual subscore > 1 point).

  6. Mucosal healing rate [at Week 12]

    Mucosal healing rate at week 12 after treatment (mucosal healing is defined as Mayo endoscopic subscore ≤ 1)

  7. Incidence, type and severity of Treatment Emergent Adverse Event (TEAE) [for 12 consecutive weeks]

    The safety and tolerability will be assessed on basis of incidence, type and severity of TEAEs as well as their relations with the investigational product .

  8. Incidence, type and severity of Serious Adverse Event (SAE) [for 12 consecutive weeks]

    The safety and tolerability will be assessed on basis of incidence, type and severity of SAEs as well as their relations with the investigational product and SAEs that lead to discontinuation of study.

  9. Incidence, type and severity of Adverse Events (AE) [for 12 consecutive weeks]

    The safety and tolerability will be assessed on basis of AEs that lead to discontinuation of study, and AEs of special interest (cardiac events as well as pulmonary function tests, ophthalmologic examinations, skin examinations, and nervous system physical examinations)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
For the stage 1:

  1. Male or female subjects aged 18-75 years (inclusive).

  2. Female subjects of childbearing potential and male subjects who have not undergone vasectomy should use at least one highly effective methods of contraception during the entire study and 4 weeks after the last dose of investigational products after signing the informed consent form.

  3. The subject has a diagnosis of UC established at least 3 months prior to screening by clinical and endoscopic evidence corroborated by a histopathology report. Subjects are confirmed to have moderate to severe active UC within 14 days prior to the first dose of the investigational product, which is based on an adapted Mayo score of 4-9, and an endoscopic subscore of ≥ 2. Endoscopy must be performed during the screening period (day -14 to day -3, allowing centralized reading and evaluation before the first dose at week 0).

  4. The subject has evidence of UC extending to the rectum with ≥15 cm involvement on endoscopy.

  5. Subjects must be UC patients who are receiving treatment. They can be enrolled if they meet any items below.

  6. Prior to the randomization visit, subjects have received oral 5-ASA (e.g., mesalazine, sulfasalazine, olsalazine, balsalazide) for at least 4 weeks with the dose stable for at least 2 weeks.

  7. Prior to the randomization visit, subjects have received oral or IV corticosteroids e.g. prednisone (daily doses ≤ 30 mg), budesonide (daily doses ≤ 9 mg), methylprednisolone (daily doses ≤ 24 mg), or equivalent dose of corticosteroids for at least 4 weeks, with the dose stable for at least 2 weeks.

  8. If oral 5-ASA or corticosteroid for treatment of UC have been recently discontinued, they must have been stopped for at least 2 weeks prior to the screening endoscopy examination which is used for Mayo score assessment.

  9. If subjects use non-prohibited concomitant medications, a stable dosing regimen must be used, that is, within 7 days prior to first dose of investigational product or within 5 half lives of the drug (whichever is longer), there's no new concomitant medications started or changes in the dose of existing non-prohibited concomitant medications.

  10. The subject who has extensive colitis or pancolitis of >8 years duration or limited colitis of >12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months prior to initial screening visit (can be performed during Screening if not performed in previous 12 months).

For subjects' entry into the study stage 2 from the stage 1:

  1. Subjects must be those with UC who participate in the study of CBP-307CN002 and have completed 12 weeks of treatment with CBP-307 or placebo in the stage 1 and have completed all the assessments (including colonoscopy) at study visit of week 12 in study stage 1.

  2. Female subjects of childbearing potential and male subjects who have not undergone vasectomy should use at least one highly effective methods of contraception during the entire study and 4 weeks after the last dose of investigational products after signing the informed consent form.

Exclusion Criteria:
UC-related exclusion criteria:

  1. At the screening visit, subjects have evidence of toxic megacolon.

  2. The subject has had, subtotal or total colectomy.

  3. The subject has an existing ileostomy, colostomy (a history of ileostomy or colostomy that has been reversed may be acceptable), or known symptomatic stenosis of the intestine.

  4. Investigator judges the subject currently requires or is anticipated to require surgical intervention for UC during the study.

  5. The subject has a history or evidence of adenomatous colonic polyps that have not been removed.

  6. Subjects were previously exposure to the following treatments:

  • Lymphocyte-depleting therapies (e.g., alemtuzumab, anti-CD4 antibody, cladribine, rituximab, ocrelizumab, cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation and daclizumab).

  • Previous treatment with D-penicillamine, leflunomide.

  1. Within 60 days prior to the screening visit, the subject has received any of the following for the treatment of UC:

  2. Intravenous immunoglobulin;

  3. Therapeutic plasma exchange (TPE).

  4. Within 30 days prior to randomization visit, the subject has received any of the following for the treatment of UC:

  5. Immunosuppressants (such as cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil), thalidomide or traditional Chinese medicine;

  6. Approved non-biologic agents or traditional Chinese medicine treatment.

  7. Patients who plan to concurrently use an immunosuppressant (such as azathioprine, 6 mercaptopurine or methotrexate) after randomization. Patients treated with azathioprine, 6-mercaptopurine or methotrexate at screening are required to discontinue it prior to the first dose of the study drug.

  8. The subject has received any investigational biologic or non-biologic agent, or approved biologic agent or biosimilars within 60 days or 5 half-lives prior to screening (whichever is longer).

Exclusion criteria for general conditions:

  1. History of uveitis or macular oedema.

  2. Clinically relevant cardiovascular conditions, including history or presence of any one of below:

  3. Ischemic heart disease or myocardial infarction; Unstable angina; History of angina pectoris caused by coronary artery spasm, or raynaud's phenomenon (Raynauds);

  4. Congestive heart failure (NYHA class III-IV), cardiac arrest;

  5. Stroke, transient ischemic attack;

  6. History of recurrent syncope or positive result of vasovagal syncope tilt test;

  7. Symptomatic bradycardia, sick sinus syndrome, sinoatrial block, second degree atrioventricular block (e.g., Mobitz type 2 atrioventricular block) or third degree atrioventricular block;

  8. Congenital long QT syndrome (LQTS), or prolonged QT interval corrected using Fridericia's formula (QTcF) in screening ECG (QTcF >450 ms in men, QTcF > 470 ms in women);

  9. Subjects at increased risk for QT prolongation due to hypokalemia or hypomagnesemia; or subjects who currently tacking medications to prolong QT interval (e.g., citalopram, chlorpromazine, haloperidol, methadone, and erythromycin) which result in risk for torsades de pointes;

  10. Under treatment or expected to taking treatment during the study with medications with a known impact on the cardiac conduction system (e.g., beta blockers, calcium channel blockers, Class Ia or Class III anti-arrhythmic drugs. [amiodarone, bromobenzylamine, sotalol, ibutilide, azimilide, dofetilide]);

  11. Hypertension (except well-controlled hypertension after pharmacotherapy); systolic blood pressure < 95 mm Hg or >140 mm Hg and diastolic blood pressure ≤ 50 mm Hg or ≥ 95 mm Hg at the screening visit;

  12. Resting heart rate < 55 times/min or ventricular rate < 55 times/min in 12-lead ECG at screening visit;

  13. Investigator deems that the 12-lead ECG at screening visit is clinically significant abnormal, such as, myocardial ischemia, any significant cardiac conduction abnormalities (such as the left bundle branch block), that would put the subject at risk or interfere with the study results;

  14. Any other significant heart disease that the investigator judges would put the subject at risk or interfere with the study results.

  15. Subjects have a family history of premature coronary heart disease.

  16. History of type 1 diabetes, uncontrolled type 2 diabetes (HbA1c > 7%) judged by investigator, patients with diabetes accompanied with significant complications, e.g., retinopathy or kidney disease.

  17. Pulmonary function test (including examinations of lung ventilation function and pulmonary gas exchange) at the screening visit shows one of the following abnormalities: forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) < 70% of normal expected value.

  18. During screening period, any of the following laboratory abnormalities:

  19. HGB < 8 g/dL;

  20. WBC count < 3.5 × 10E9/L;

  21. Neutrophils count < 1.5 × 10E9/L;

  22. Lymphocyte count < 0.8 × 10E9/L;

  23. Platelet count < 100 × 10E9/L or >1200 × 10E9/L;

  24. Serum creatinine > 124 μmol/L for female or > 141 μmol/L for male;

  25. Abnormal liver function test druring the screening period, such as abonormalities in alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (γ-GT), alkaline phosphatase (ALK) or serum total bilirubin, which suggests liver diseases or liver function impairment.

  26. If female, the subject is intending to become pregnant before, during, or within 4 weeks after participating in the study or intending to donate ova during such period.

  27. If male, the subject intends to donate sperm during the study or for 4 weeks thereafter.

Exclusion criteria for infectious diseases:

  1. The subject has evidence of known active infection during the screening period.

  2. The subject has evidence of treatment for Clostridioides difficile (C. difficile) infection or other intestinal pathogen with 28 days prior to first dose of study drug.

  3. Active or latent tuberculosis (TB) evidenced.

  4. Chronic hepatitis B virus (HBV) infection* or chronic hepatitis C virus (HCV) infection**.

  5. The subject has any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation).

  6. The subject has received any live vaccine within 30 days prior to screening, or subjects are scheduled for immunization with any live vaccine during the study or within 1 month after the last dose of the investigational product.

  7. Positive syphilis antibody at screening.

  8. Subjects with a history of more than one episode of herpes zoster, or a history of disseminated herpes zoster or disseminated herpes simplex.

For subjects' entry into the study stage 2 from the stage 1:

  1. Subjects currently have evidence of active or untreated latent tuberculosis.

  2. Subjects currently have active or chronic recurrent infections, and in the opinion of the investigator subjects are not appropriate to participate in the stage 2 of the study.

  3. History of uveitis or macular oedema.

  4. Subjects had received any of the following treatments after administration of the first dose in the stage 1 of the study:

  • Biological product;

  • Prednisone>30 mg/day, budesonide>9 mg/day, methylprednisolone>24 mg/day or equivalent dose of steroid treatment;

  • Immunosuppressant (such as azathioprine and 6-mercaptopurine or methotrexate).

  1. Investigator deems that the 12-lead ECG results at the study visit of week 12 during study stage 1 is clinically significant abnormal, such as myocardial ischemia, any significant cardiac conduction abnormalities (such as the left bundle branch block), any abnormality that would put the subject at risk or interfere with the study results.

  2. Pulmonary function test (including examinations of lung ventilation function and pulmonary gas exchange) of subjects at the study visit of week 12 during the study stage 1 shows 1 of the following abnormalities: forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) < 50% of normal predicted value.

  3. Subjects' laboratory measurements at week 12 visit during the study stage 1 meet any of the following criteria:

  • AST or ALT> 3 ULN;

  • Absolute lymphocyte count < 0.2×10E9/L;

  • Serum creatinine > 124 μmol/L (in females) or > 141 μmol/L (in males)

  1. Any other reason that in the opinion of the investigator may interfere with subject compliance or evaluation of the results of the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Connect Investigative Site 2316 Phoenix Arizona United States 85018
2 Connect Investigative Site 2308 Mission Hills California United States 91345
3 Connect Investigative Site 2314 Hialeah Florida United States 33016
4 Connect Investigative Site 2309 Homestead Florida United States 33032
5 Connect Investigative Site 2320 Kissimmee Florida United States 34741
6 Connect Investigative Site 2318 Miami Florida United States 33126
7 Connect Investigative Site 2302 Orlando Florida United States 32803
8 Connect Investigative Site 2304 Orlando Florida United States 32810
9 Connect Investigative Site 2306 Orlando Florida United States 32819
10 Connect Investigative Site 2307 Atlanta Georgia United States 30309
11 Connect Investigative Site 2315 Cincinnati Ohio United States 45219
12 Connect Investigative Site 2321 Oklahoma City Oklahoma United States 73102
13 Connect Investigative Site 2311 Cypress Texas United States 90212
14 Connect Investigative Site 2319 San Antonio Texas United States 78229
15 Connect Investigative Site 2018 Hefei Anhui China 230001
16 Connect Investigative Site 2004 Hefei Anhui China 230022
17 Connect Investigative Site 2008 Beijing Beijing China 100050
18 Connect Investigative Site 2001 Beijing Beijing China 100730
19 Connect Investigative Site 2015 Jilin Changchun China 130021
20 Connect Investigative Site 2006 Fuzhou Fujian China 350001
21 Connect Investigative Site 2012 Xiamen Fujian China 361004
22 Connect Investigative Site 2003 Guangzhou Guangdong China 510120
23 Connect Investigative Site 2009 Guangzhou Guangdong China 510655
24 Connect Investigative Site 2017 Shenzhen Guangdong China 518035
25 Connect Investigative Site 2021 Shenzhen Guangdong China 518053
26 Connect Investigative Site 2030 Nanning Guangxi China 168600
27 Connect Investigative Site 2034 Haikou Hainan China 570311
28 Connect Investigative Site 2026 Shijiazhuang Hebei China 050000
29 Connect Investigative Site 2041 Shijiazhuang Hebei China 050011
30 Connect Investigative Site 2022 Zhengzhou Henan China 450052
31 Connect Investigative Site 2016 Wuhan Hubei China 430022
32 Connect Investigative Site 2005 Wuhan Hubei China 430030
33 Connect Investigative Site 2027 Nanjing Jiangsu China 210002
34 Connect Investigative Site 2031 Nanjing Jiangsu China 210006
35 Connect Investigative Site 2023 Nanjing Jiangsu China 210036
36 Connect Investigative Site 2033 Suzhou Jiangsu China 215004
37 Connect Investigative Site 2046 Nanchang Jiangxi China 330006
38 Connect Investigative Site 2025 Dalian Liaoning China 116027
39 Connect Investigative Site 2040 Shenyang Liaoning China 117004
40 Connect Investigative Site 2028 Jinan Shandong China 250012
41 Connect Investigative Site 2024 Qingdao Shandong China 266000
42 Connect Investigative Site 2011 Shanghai Shanghai China 200025
43 Connect Investigative Site 2007 Shanghai Shanghai China 200040
44 Connect Investigative Site 2019 Shanghai Shanghai China 200065
45 Connect Investigative Site 2035 Shanghai Shanghai China 200080
46 Connect Investigative Site 2038 Shanghai Shanghai China 200433
47 Connect Investigative Site 2020 Taiyuan Shanxi China 030001
48 Connect Investigative Site 2013 Chengdu Sichuan China 610041
49 Connect Investigative Site 2043 Chongqing Sichuan China 400037
50 Connect Investigative Site 2047 Hangzhou Zhejiang China 310003
51 Connect Investigative Site 2032 Hangzhou Zhejiang China 310009
52 Connect Investigative Site 2045 Wenzhou Zhejiang China 325027
53 Connect Investigative Site 2151 Karachi Sindh Province Pakistan 74800
54 Connect Investigative Site 2152 Karachi Sindh Province Pakistan 75270
55 Connect Investigative Site 2211 Dnipro Ukraine 49005
56 Connect Investigative Site 2217 Ivano-Frankivsk Ukraine 76018
57 Connect Investigative Site 2202 Kharkiv Ukraine 61037
58 Connect Investigative Site 2208 Kharkiv Ukraine 61124
59 Connect Investigative Site 2205 Kyiv Ukraine 1135
60 Connect Investigative Site 2220 Kyiv Ukraine 8173
61 Connect Investigative Site 2215 Lviv Ukraine 79005
62 Connect Investigative Site 2216 Lviv Ukraine 79010
63 Connect Investigative Site 2218 Uzhhorod Ukraine 88000
64 Connect Investigative Site 2209 Vinnytsia Ukraine 21021
65 Connect Investigative Site 2214 Zaporizhzhia Ukraine 69035

Sponsors and Collaborators

  • Suzhou Connect Biopharmaceuticals, Ltd.

Investigators

  • Study Director: Suzhou Connect, Suzhou Connect Biopharmaceuticals, Ltd.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Suzhou Connect Biopharmaceuticals, Ltd.
ClinicalTrials.gov Identifier:
NCT04700449
Other Study ID Numbers:
  • CBP-307CN002
First Posted:
Jan 7, 2021
Last Update Posted:
Apr 27, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Colitis
Colitis, Ulcerative
Ulcer

Study Results

No Results Posted as of Apr 27, 2022